218m shares on issue.The risk is whether or not they can sell Ropren in Russia in meaningful volumes before they run out of cash (assuming no plan B)No problem with that.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game